Scribe Therapeutics (SCTX) – Investment Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Scribe Therapeutics (NASDAQ: SCTX) in the last few weeks:

• 9/1/2026 – Scribe Therapeutics was upgraded by Zacks Research to “hold”.
• 8/31/2026 – Scribe Therapeutics is now covered by HC Wainwright. They set a “buy” rating and a $60.00 price target on the stock.
• 8/18/2026 – Scribe Therapeutics is now covered by Guggenheim. They set a “buy” rating and a $50.00 price target on the stock.
• 8/18/2026 – Scribe Therapeutics is now covered by Wells Fargo & Company. They set an “overweight” rating and a $60.00 price target on the stock.
• 8/18/2026 – Scribe Therapeutics is now covered by Wells Fargo & Company. They set an “overweight” rating and a $60.00 price target on the stock.
• 8/18/2026 – Scribe Therapeutics is now covered by Guggenheim. They set a “buy” rating and a $50.00 price target on the stock.
• 8/18/2026 – Scribe Therapeutics is now covered by Leerink Partners. They set an “outperform” rating and a $37.00 price target on the stock.
• 8/1/2026 – Scribe Therapeutics was upgraded by Wall Street Zen to “hold”.

Insider Activity at Scribe Therapeutics

In related news, Director Behzad Aghazadeh bought 7,905 shares of the firm’s stock in a transaction that occurred on Tuesday, July 28th. The shares were acquired at an average cost of $18.25 per share, for a total transaction of $144,266.25. Following the acquisition, the director directly owned 3,088,888 shares of the company’s stock, valued at $56,372,206. The trade was a 0.26% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO David Parrot bought 2,666 shares of the stock in a transaction on Thursday, July 23rd. The stock was acquired at an average cost of $15.00 per share, for a total transaction of $39,990.00. Following the acquisition, the chief financial officer directly owned 1,333 shares in the company, valued at approximately $19,995. The trade was a -200.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 3,727,237 shares of company stock valued at $56,291,746 over the last quarter.

Scribe Therapeutics Inc is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Scribe Therapeutics Inc is based in ALAMEDA, Calif.